Efficacy and tolerability of zuranolone in patients with depression: a meta-analysis of randomized controlled trials.

ABSTRACT: Background: As a novel antidepressant drug, zuranolone has been initially applied in treating depression. This study investigated the efficacy and safety of its administration in patients with depression. Methods: The Embase, PubMed, and Cochrane library databases were searched for available studies up to 1 Nov 2023. The primary outcome was the change on day 15 depression severity scores compared to baseline. Secondary outcomes included remission and response rates on day 15. Safety outcomes included incidence of treatment-emergent adverse events (TEAEs) and individual AEs. Trial sequential analysis (TSA) was used to evaluate the ideal samplesize. Results: Six studies with 1884 patients were included. Zuranolone offered significantly greater changes in day 15 depressio

SUBMITTER: Qiu Y 

PROVIDER: S-EPMC10823021 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature